CPAP Effect on the Progression of Diabetic Retinopathy in Patients With Sleep Apnea

Exclusion Criteria

• •Prior systemic treatment for diabetic retinopathy, with the exception of nutritional supplements or vitamins.
• •Pre-treatment with anti-vascular endothelial growth factor (VEGF) drugs in the studied eye. It is allowed a pre-treatment with anti-VEGF approved in the other eye more than 3 months ago.
• •Prior systemic anti-VEGF, experimental or approved treatment, three months before the inclusion.
• •Evidence of inflammation or infection in or around the studied eye.
• •Treatment with troglitazone in the last three months.
• •Eye surgery (including cataract surgery) in the studied eye three months before the inclusion.
• •Late macular degeneration (geographical with foveal or neovascular involvement).
• •Vascular retinal diseases, such as vascular occlusions.
• •Previous diagnosis of other eye diseases that could lead to a decrease in visual acuity.
• •Systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 110 mm Hg at the baseline visit.
• •Stroke, transient ischemic attack, acute coronary syndrome, or hospitalization for heart failure worsening, within the previous 30 days.
• •Professional drivers, risk profession or respiratory failure.
• •Severe daytime sleepiness (Epworth sleepiness scale \>18)
• •Concomitant treatment with high doses of acetylsalicylic acid (\> 500 mg/day) or continuous treatment with non-steroidal anti-inflammatory drugs
• •Previous treatment with CPAP
• •Participation in another clinical trial within the 30 days prior to randomization.